TY - JOUR
TI - Lipid profile and thyroid hormone concentrations in children with epilepsy treated with oxcarbazepine monotherapy: A prospective long-term study
AU - Garoufi, A.
AU - Koemtzidou, E.
AU - Katsarou, E.
AU - Dinopoulos, A.
AU - Kalimeraki, I.
AU - Fotinou, A.
AU - Drakatos, A.
AU - Attilakos, A.
JO - European Journal of Paediatric Neurology
PY - 2014
VL - 21
TODO - 1
SP - 118-123
PB - 
SN - 1090-3798
TODO - 10.1111/ene.12262
TODO - cholesterol;  gamma glutamyltransferase;  high density lipoprotein cholesterol;  liothyronine;  lipid;  lipoprotein A;  low density lipoprotein cholesterol;  oxcarbazepine;  thyroid hormone;  thyrotropin;  thyroxine;  triacylglycerol, adolescent;  anticonvulsant therapy;  article;  chemiluminescence immunoassay;  child;  cholesterol blood level;  clinical article;  clinical evaluation;  controlled study;  drug efficacy;  drug safety;  electrochemiluminescence immunoassay;  female;  focal epilepsy;  free liothyronine index;  free thyroxine index;  gamma glutamyl transferase blood level;  human;  hyperlipidemia;  liothyronine blood level;  lipid analysis;  lipoprotein blood level;  long term care;  male;  monotherapy;  obesity;  predictive value;  preschool child;  priority journal;  prospective study;  school child;  serum;  side effect;  thyroid disease;  thyroid function test;  thyroid hormone blood level;  thyrotropin blood level;  thyroxine blood level;  treatment duration;  triacylglycerol blood level, children;  epilepsy;  lipids;  oxcarbazepine;  thyroid hormones, Adolescent;  Anticonvulsants;  Carbamazepine;  Child;  Child, Preschool;  Epilepsy;  Female;  Humans;  Immunoassay;  Lipids;  Longitudinal Studies;  Luminescent Measurements;  Male;  Prospective Studies;  Thyroid Hormones
TODO - Background and purpose: To evaluate prospectively the changes and possible associations in lipid and thyroid profiles in children treated with oxcarbazepine (OXC) monotherapy. Methods: Serum total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TGs), lipoprotein (a) [Lp(a)], free thyroxine (FT4), free triiodothyronine (FT3), thyrotropin (TSH) and gamma-glutamyltransferase (GGT) concentrations were measured in 23 children with epilepsy, before and at 8 and 18months of OXC monotherapy. Results: Total cholesterol was significantly increased at 8months (P=0.033), whereas LDL-C was significantly increased at 8 and 18months (P<0.001 and P=0.004, respectively) of treatment. Lp(a) was significantly increased at 8months (P=0.042) and borderline significantly increased at 18months (P=0.050) of treatment. FT4 was significantly decreased at 8 and 18months (P<0.001 and P=0.002, respectively), and TSH levels were significantly increased at 8 and 18months (P=0.002 and P=0.001, respectively) of OXC monotherapy. GGT levels were significantly increased at 8 and 18months (P<0.001) of treatment. There were no significant alterations in HDL-C, TGs and FT3 levels during the study. Significant positive correlations were found between GGT and LDL-C levels at 8 (r=0.468, P=0.024) and 18months (r=0.498, P=0.016), and between TSH and TC at 18months (r=0.508, P=0.013) of treatment. Conclusions: OXC monotherapy may cause significant and persistent alterations in lipid and thyroid profiles in children with epilepsy. The increase in LDL-C and TC levels may be associated with liver enzymes induction and thyroid dysfunction. Further long-term prospective studies are required to confirm these findings and to determine their clinical significance. © 2013 EFNS.
ER -